FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
Klow Blend 50/10/10/10mg research peptide vial
Recovery

Klow Blend

BPC-157 + TB-500 + GHK-Cu + KPV

A four-peptide research blend adding KPV to the Glow recovery profile.

$180

In stock · ships in 1–2 business days

  • ✓ 99.87% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
blendrecovery

Research Summary

The Klow Blend adds the KPV tripeptide to BPC-157, TB-500, and GHK-Cu, studied in preclinical models that combine tissue-repair and inflammatory-signaling pathways. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

Klow Blend: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is the Klow Blend?

The Klow Blend is a single lyophilized vial containing four research peptides: BPC-157, TB-500, the copper peptide GHK-Cu, and the tripeptide KPV. It adds KPV to the three peptides in our Glow Blend. Each component has its own page: BPC-157, TB-500, GHK-Cu, and KPV.

Research on this specific four-peptide combination in one vial is limited. The work summarized below was done on each peptide individually. This page makes no claim that the four components interact, add to one another, or produce a combined effect.

Klow Blend molecular identity
Component 1: BPC-157GEPPPGKPADDAGLV, 15 amino acids, C62H98N16O22, 1419.5 g/mol (PubChem CID 9941957)
Component 2: TB-500Indexed by PubChem as Ac-LKKTETQ, the acetylated 17-23 fragment of thymosin beta-4, C38H68N10O14, 889.0 g/mol (PubChem CID 62707662)
Component 3: GHK-CuCopper(II) complex of the tripeptide Gly-His-Lys (GHK); GHK peptide C14H24N6O4, 340.38 g/mol (PubChem CID 73587)
Component 4: KPVLys-Pro-Val, alpha-MSH (11-13), C16H30N4O4, 342.43 g/mol (PubChem CID 125672)
FormLyophilized powder, four peptides combined in a single vial
Labeled strength50/10/10/10mg

The four components

BPC-157

A synthetic 15-residue fragment of a protein first isolated from human gastric juice [1]. In rat tendon fibroblasts it increased migration and survival, linked to focal adhesion kinase and paxillin phosphorylation [5]. A 2025 systematic review found the evidence almost entirely preclinical and concluded the peptide should be regarded as investigational [6].

TB-500

PubChem indexes TB-500 as Ac-LKKTETQ, an acetylated copy of residues 17 to 23 of the actin-binding protein thymosin beta-4 [2], although the name is also used for synthetic full-length thymosin beta-4. A 2010 review associated the LKKTETQ region of the parent protein with angiogenesis, wound healing, and cell migration in experimental systems [7]. Findings for the full protein cannot automatically be attributed to the fragment; see the TB-500 page.

GHK-Cu

GHK (glycyl-L-histidyl-L-lysine) is a copper-binding tripeptide isolated from human plasma [3] [8]. Its copper complex stimulated collagen synthesis in fibroblast cultures in a 1988 study [8]. Our article on GHK-Cu peptide research covers the wider literature.

KPV

KPV is the C-terminal tripeptide (residues 11 to 13) of alpha-melanocyte-stimulating hormone [4]. In human intestinal epithelial and T-cell lines, KPV entered cells through the PepT1 transporter and inhibited NF-kappaB and MAP kinase inflammatory signaling; in mice it reduced the incidence of chemically induced colitis [9]. A 2008 review explained that KPV drew interest because it retained anti-inflammatory activity in experimental systems without the pigmentary action of the full hormone [10]. FDA reports no human exposure data for KPV products [12].

What is known about the combination

We did not find published research on these four peptides together, or on KPV combined with any of the other three. The only combination data we found involve two of the components: a 2026 rat Achilles tendon study compared BPC-157, TB-500, and both together, and the authors reported no additional effect in the combined group over either peptide alone [11]. That study did not include GHK-Cu or KPV, and did not use a pre-combined vial.

The four components were studied in different model systems, for different endpoints, by different research groups. Nothing in that literature describes how they behave stored together, and human evidence is very limited or absent for each [6] [12]. The findings above should not be read as evidence of safety or benefit in people.

See also our BPC-157 research overview and other research peptides in this category.

Regulatory status

  • Not FDA approved. BPC-157, TB-500, and KPV are unapproved peptides, not FDA-approved drugs [13], and this blend is not an approved drug.
  • Compounding. FDA's list of bulk drug substances that may present significant safety risks (current as of April 22, 2026) places all four components among withdrawn nominations: BPC-157, the thymosin beta-4 fragment known as TB-500, KPV, and GHK-Cu (for certain routes of administration). FDA notes limited or missing human safety information for each [12].
  • Advisory committee vote. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend each of BPC-157, TB-500, and KPV for the 503A bulks list, against FDA staff's recommendation. GHK-Cu was not reviewed at that meeting. The votes are non-binding, and FDA had not acted on them at the time of this review [13] [14].
  • Sport. The World Anti-Doping Agency 2026 Prohibited List names BPC-157 under S0 and "Thymosin-β4 and its derivatives e.g. TB-500" under S2.3 [15].

Rejuvatide supplies the Klow Blend strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

The Klow Blend has its own certificate from an independent laboratory. It reports HPLC purity of the combined material, confirms the identity of all four components (GHK-Cu, KPV, TB-500, and BPC-157) by LC-MS, and includes an endotoxin result under USP <85>. The certificate is shown below and in our COA library, published exactly as the laboratory issued it.

Storage of lyophilized material

The Klow Blend ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of Klow Blend.

99.87%HPLC purity
Lot 60730-30Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

Klow Blend FAQ

What is in the Klow Blend?

Four research peptides in one lyophilized vial: BPC-157, TB-500, GHK-Cu, and KPV, labeled 50/10/10/10mg.

How is it different from the Glow Blend?

The Klow Blend adds KPV, a tripeptide fragment of alpha-MSH studied in inflammatory-signaling research, to the BPC-157, TB-500, and GHK-Cu found in the Glow Blend.

Has this four-peptide combination been studied?

No published studies of the four together were found. The research described on this page concerns each peptide individually.

Is the Klow Blend FDA approved?

No. Neither the blend nor its components are FDA-approved drugs. July 2026 advisory committee votes on BPC-157, TB-500, and KPV were non-binding, and FDA had not acted on them as of October 12, 2026.

How is the Klow Blend tested?

The blend has its own independent laboratory certificate covering HPLC purity, LC-MS identity of all four components, and endotoxin under USP <85>, published on this page and in the COA library.

Is the Klow Blend for human use?

No. Rejuvatide sells it for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. PubChem. BPC 157, Compound CID 9941957. National Library of Medicine. Source
  2. PubChem. TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH), Compound CID 62707662. National Library of Medicine. Source
  3. PubChem. Glycyl-L-histidyl-L-lysine, Compound CID 73587. National Library of Medicine. Source
  4. PubChem. Msh (11-13), Lys-Pro-Val, Compound CID 125672. National Library of Medicine. Source
  5. Chang CH, Tsai WC, Lin MS, et al. J Appl Physiol (1985). 2011;110(3):774-80. PubMed 21030672
  6. Vasireddi N, Hahamyan H, Salata MJ, et al. HSS J. 2025;21(4):485-495. PubMed 40756949
  7. Sosne G, Qiu P, Goldstein AL, et al. FASEB J. 2010;24(7):2144-51. PubMed 20179146
  8. Maquart FX, Pickart L, Laurent M, et al. FEBS Lett. 1988;238(2):343-6. PubMed 3169264
  9. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. Gastroenterology. 2008;134(1):166-78. PubMed 18061177
  10. Brzoska T, Luger TA, Maaser C, et al. Endocr Rev. 2008;29(5):581-602. PubMed 18612139
  11. Biçer O, Adanir O, Güleryüz Y, et al. Jt Dis Relat Surg. 2026;37(3):822-837. PubMed 42542926
  12. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  13. Pharmaceutical Executive. FDA panel votes to loosen restrictions on four peptides (July 24, 2026). Source
  14. Kelley Drye & Warren LLP. FDA advisory committee recommends several peptides for compounding for various uses despite staff opposition: what stakeholders need to know (July 30, 2026). Source
  15. World Anti-Doping Agency. The 2026 Prohibited List, S0 Non-Approved Substances and S2.3 Growth Factors and Growth Factor Modulators. Source